The development of high throughput technologies other than WB will be necessary to validate in a large cohort of patients the value of GAPDH and PRDX2 as candidate biomarkers for OSA diagnosis and prognosis, respectively. The gene discussed is PRDX2; the disease is obstructive sleep apnea syndrome.